Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis

Fig. 1

(A) Sensitivity of p53 mutated or wild-type TNBC cell lines to doxorubicin. IC50 values were calculated by CellTiter-Glo following 72 h doxorubicin exposure. (B) Effects of DOX alone or in combination with OKI-005 for CAL-51 (wild-type p53), MDA-MB-231 (mutant p53), Hs 578T (mutant p53), and CAL-120 (mutant p53) as measured by CellTiter-Glo after 72 h drug exposure. (C) Synergistic effects of DOX and OKI-005. Bliss scores were calculated from the data in Fig. 1B using Synergy Finder+. (D) Anti-proliferative effects of DOX in combination with OKI-005 measured by live cell imaging for 48 h. Statistical analysis comparing single agent to combination was determined by ordinary one-way ANOVA with Tukey correction (* = p < 0.05)

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us